Auxilium files for EU approval of Xiapex for Peyronies disease Auxilium and Swedish Orphan Biovitrum AB announced that Sobi has filed for an extension of the label for Xiapex - collagenase clostridium histolyticum - with the EMA to include the indication of Peyronie's disease. The filing is based on positive safety and efficacy outcome data from two double-blind placebo-controlled studies. Sobi is Marketing Authorisation Holder for Xiapex in 28 EU member countries as well as Norway and Iceland.
News For AUXL From The Last 14 Days
Check below for free stories on AUXL the last two weeks.